Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Demant A/S (DEMANT.CO)
DKK279.00
+2.40 (+0.87%)
DK CPH Healthcare Medical - Devices
Address
Kongebakken 9 2765
Smørum, DK
Smørum, DK
CEO
Søren Nielsen
Website
demant.com
IPO
2000-05-08
ISIN DK0060738599
Also trades on
NASDAQ Copenhagen · DEMANT.CO (DKK)
Other OTC · WILLF (USD)
Other OTC · WILYY (USD)
Description
Demant A/S operates as a prominent international entity within the hearing health and audio technology sectors, extending its reach across Europe, North America, the Pacific region, and Asia. The company's activities are structured into two core divisions: Hearing Healthcare and Communications. The Hearing Healthcare segment focuses on the development, sale, and support of hearing aids, in addition to offering a range of diagnostic tools and associated services. Conversely, the Communications segment delivers headsets for professional contact centers, general office environments, and the gaming industry, all distributed under the EPOS brand. Established in 1904, Demant A/S, which was formerly known as William Demant Holding A/S until its name change in March 2019, maintains its corporate headquarters in Smørum, Denmark.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
DKK279.00
+2.40 (+0.87%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
404.9K
Beta
0.75
Float Shares
83.77M
Free Float %
39.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.79% | +0.89% | +23.86% | +27.13% | +14.14% | +17.24% | -0.56% | -6.95% | -25.00% | +75.83% | +421.25% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
279.00
DCF (Unlevered)
516.27
+85.0%
DCF (Levered)
516.53
+85.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
63% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 10 | 0 |
| Hold | 6 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Quality scores
Altman Z-Score
3.37
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+2.9% Q4'25: +4.0% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%-34.1% Q4'25: -62.7% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+13.5% Q4'25: +17.2% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+15.7% ★ Q4'25: +15.0% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+8.6% ★ Q4'25: +16.6% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%-2.7% ★ Q4'25: -5.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×4.59× Q4'25: 2.00× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 17 Rev. Ana. 16 EPS Ana. |
Dec 2027 18 Rev. Ana. 16 EPS Ana. |
Dec 2028 17 Rev. Ana. 13 EPS Ana. |
Dec 2029 14 Rev. Ana. 11 EPS Ana. |
Dec 2030 8 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.67B
est: 10.53B (+1.3%)
|
12.00B
est: 12.02B (-0.1%)
|
13.19B
est: 13.05B (+1.1%)
|
13.94B
est: 13.98B (-0.3%)
|
14.95B
est: 14.81B (+0.9%)
|
14.47B
est: 14.40B (+0.5%)
|
18.39B
est: 18.52B (-0.7%)
|
19.71B
est: 19.51B (+1.0%)
|
22.44B
est: 22.84B (-1.7%)
|
22.42B
est: 22.45B (-0.1%)
|
23.08B
est: 22.83B (+1.1%)
|
25.81B
25.44B – 26.27B
+13.1% YoY
|
27.51B
26.90B – 28.23B
+6.6% YoY
|
29.32B
29.28B – 29.37B
+6.6% YoY
|
31.15B
30.58B – 31.84B
+6.2% YoY
|
33.11B
32.50B – 33.84B
+6.3% YoY
|
| EBITDA |
2.17B
est: 2.36B (-7.9%)
|
2.28B
est: 2.69B (-15.5%)
|
2.70B
est: 2.92B (-7.5%)
|
2.74B
est: 3.13B (-12.4%)
|
2.88B
est: 3.32B (-13.1%)
|
2.41B
est: 3.22B (-25.3%)
|
4.46B
est: 4.15B (+7.6%)
|
4.29B
est: 4.37B (-1.7%)
|
5.25B
est: 5.09B (+3.0%)
|
5.80B
est: 5.01B (+15.9%)
|
5.14B
est: 5.09B (+0.9%)
|
5.76B
5.68B – 5.86B
+13.1% YoY
|
6.14B
6.00B – 6.30B
+6.6% YoY
|
6.54B
6.53B – 6.55B
+6.6% YoY
|
6.95B
6.82B – 7.10B
+6.2% YoY
|
7.39B
7.25B – 7.55B
+6.3% YoY
|
| EBIT |
1.85B
est: 1.71B (+8.0%)
|
1.90B
est: 1.95B (-3.0%)
|
2.33B
est: 2.12B (+9.8%)
|
2.33B
est: 2.27B (+2.5%)
|
1.96B
est: 2.41B (-18.8%)
|
1.40B
est: 2.34B (-40.4%)
|
3.45B
est: 3.01B (+14.5%)
|
3.12B
est: 3.17B (-1.7%)
|
3.95B
est: 3.99B (-0.9%)
|
4.37B
est: 3.92B (+11.4%)
|
3.62B
est: 3.99B (-9.3%)
|
4.51B
4.45B – 4.59B
+13.1% YoY
|
4.81B
4.70B – 4.93B
+6.6% YoY
|
5.12B
5.12B – 5.13B
+6.6% YoY
|
5.44B
5.34B – 5.56B
+6.2% YoY
|
5.78B
5.68B – 5.91B
+6.3% YoY
|
| Net Income |
1.44B
est: 1.16B (+23.7%)
|
1.46B
est: 1.26B (+16.1%)
|
1.75B
est: 1.56B (+12.6%)
|
1.82B
est: 1.78B (+2.7%)
|
1.46B
est: 1.35B (+7.9%)
|
1.12B
est: 844.58M (+32.7%)
|
2.51B
est: 2.29B (+9.8%)
|
2.08B
est: 2.23B (-6.5%)
|
1.80B
est: 2.43B (-26.1%)
|
2.39B
est: 2.58B (-7.5%)
|
1.55B
est: 2.37B (-34.8%)
|
2.54B
2.42B – 2.92B
+7.4% YoY
|
3.10B
2.89B – 3.58B
+21.9% YoY
|
3.53B
3.12B – 4.04B
+14.0% YoY
|
4.13B
4.03B – 4.25B
+17.0% YoY
|
4.65B
4.54B – 4.79B
+12.6% YoY
|
| SGA |
5.30B
est: 5.40B (-1.9%)
|
6.33B
est: 6.17B (+2.6%)
|
6.82B
est: 6.70B (+1.8%)
|
7.38B
est: 7.18B (+2.8%)
|
8.27B
est: 7.60B (+8.8%)
|
7.91B
est: 7.39B (+7.0%)
|
9.18B
est: 9.51B (-3.5%)
|
10.27B
est: 10.01B (+2.6%)
|
11.04B
est: 11.61B (-4.9%)
|
11.39B
est: 11.41B (-0.2%)
|
12.05B
est: 11.61B (+3.8%)
|
13.12B
12.94B – 13.36B
+13.1% YoY
|
13.99B
13.67B – 14.35B
+6.6% YoY
|
14.91B
14.88B – 14.93B
+6.6% YoY
|
15.84B
15.55B – 16.19B
+6.2% YoY
|
16.83B
16.52B – 17.20B
+6.3% YoY
|
| EPS |
5.30
est: 5.34 (-0.8%)
|
5.53
est: 5.79 (-4.4%)
|
6.84
est: 7.17 (-4.7%)
|
7.32
est: 8.17 (-10.4%)
|
6.00
est: 6.24 (-3.8%)
|
4.68
est: 3.89 (+20.4%)
|
10.70
est: 10.53 (+1.6%)
|
9.21
est: 10.30 (-10.6%)
|
8.04
est: 11.47 (-29.9%)
|
11.10
est: 12.19 (-8.9%)
|
7.31
est: 11.50 (-36.4%)
|
12.83
11.43 – 13.81
+11.6% YoY
|
15.05
13.67 – 16.96
+17.2% YoY
|
17.42
14.79 – 19.10
+15.8% YoY
|
19.55
19.08 – 20.12
+12.2% YoY
|
22.02
21.50 – 22.66
+12.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
7.15B
OE per share TTM
33.55
Owner's Yield
13.56%
Maintenance CapEx ratio
50.32%
Maint CapEx / Avg PPE
25.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 232 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X HealthTech ETF HEAL | 3.07% | 919.7K | 0.50% |
| 2 | iShares MSCI Denmark ETF EDEN | 1.30% | 2.67M | 0.53% |
| 3 | Global X - Aging Population ETF AGNG | 0.61% | 520.1K | 0.50% |
| 4 | iShares MSCI Europe Mid-Cap Equal Weight UCITS ETF IEFS.L | 0.54% | 207.1K | 0.25% |
| 5 | iShares STOXX Europe Small 200 UCITS ETF (DE) EXSE.DE | 0.49% | 3.34M | 0.20% |
| 6 | Amundi MSCI Nordic UCITS ETF - EUR (C) CN1G.DE | 0.24% | 835.2K | 0.25% |
| 7 | Xtrackers MSCI Nordic UCITS ETF 1D XDN0.L | 0.23% | 2.96M | 0.30% |
| 8 | Amundi MSCI Europe Ex EMU ESG Selection UCITS ETF Acc CU9.PA | 0.23% | 603.9K | 0.30% |
| 9 | iShares MSCI Europe Health Care Sector UCITS ETF ESIH.L | 0.19% | 1.93M | 0.18% |
| 10 | iShares STOXX Europe 600 Health Care UCITS ETF (DE) EXV4.DE | 0.19% | 1.55M | 0.46% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
144.3K
Shares Outstanding
210.90M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Søren Nielsen | Chief Executive Officer, President & Member of Executive Board | 14M | male |
| René Schneider | Chief Financial Officer, President of Group Services & Member of Executive Board | 7M | male |
| Niels Wagner | President of Hearing Care & Member of Executive Board | 6M | male |
| Sara Munch Andersen | Head of Group Privacy & Compliance | — | — |
| Stine Brandenhof | Group General Counsel | — | — |
| Anne-Karen Hunt | President of Diagnostics Business Area | — | female |
| Trine Kromann-Mikkelsen | Vice President of Corporate Communication and Sustainability | — | female |
| Gustav Kallehave Hoegh | Investor Relations Officer | — | — |
| Peter Pudselykke | Head of Investor Relations (Leave of Absence) | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DEMANT.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
